About 88 percent of patients who took Tagrisso were alive at five years, and the placebo had a 78 percent survival rate, according to a June 2 news release. Those in the placebo group who recurred with metastatic disease had the chance to take Tagrisso as a subsequent treatment.
The participants had early-stage, epidermal growth factor receptor-mutated non-small cell lung cancer. A median overall survival rate was not reached within months but was achieved after five years.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
